Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
Amy S PallerElaine C SiegfriedMichael J CorkAndreas WollenbergPeter D ArkwrightMercedes E GonzalezBenjamin LockshinZhen ChenAshish BansalNoah A LevitRandy PrescillaPublished in: Paediatric drugs (2022)
ClinicalTrials.gov: NCT03346434, part B.